Sivia Capital Partners LLC Buys New Shares in IQVIA Holdings Inc. $IQV

Key Points

• Sivia Capital Partners LLC has made a new investment in IQVIA Holdings Inc., purchasing 3,259 shares valued at approximately $514,000.
• IQVIA's quarterly earnings report showed an EPS of $2.81, surpassing analysts' expectations of $2.77, demonstrating a 5.3% revenue increase compared to the previous year.
• Analysts have generally recommended a "Moderate Buy" rating for IQVIA, with an average price target of $229.64, indicating positive sentiment surrounding the stock's potential performance.

Sivia Capital Partners LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,259 shares of the medical research company's stock, valued at approximately $514,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Canada Pension Plan Investment Board boosted its stake in IQVIA by 7.3% in the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after buying an additional 312,807 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after buying an additional 798,534 shares during the last quarter. American Century Companies Inc. boosted its position in shares of IQVIA by 26.8% during the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock valued at $253,695,000 after buying an additional 304,258 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock valued at $251,852,000 after buying an additional 40,699 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of IQVIA by 13.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock valued at $273,766,000 after buying an additional 167,057 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on IQV. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday, September 3rd. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Truist Financial raised their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, UBS Group raised their price objective on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $229.64.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Down 1.5%

Shares of IQV stock traded down $2.91 during mid-day trading on Friday, hitting $187.29. The stock had a trading volume of 2,104,117 shares, compared to its average volume of 1,124,593. The firm has a market capitalization of $31.84 billion, a P/E ratio of 27.10, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $245.20. The firm's 50-day moving average is $184.79 and its two-hundred day moving average is $167.31.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.